Biomarkers of Bone Resorption in Metastatic Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01233557
Recruitment Status : Completed
First Posted : November 3, 2010
Last Update Posted : November 5, 2015
Information provided by (Responsible Party):
University of Aberdeen

Brief Summary:
Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.

Condition or disease
Metastatic Prostate Cancer

Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates
Study Start Date : September 2010
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Bone Metastases

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
men with hormone sensitive prostate cancer with bone metastases

Inclusion Criteria:

  • prostate cancer with bone metastases
  • hormone sensitive

Exclusion Criteria:

  • inadequate renal function
  • ongoing dental problems
  • previous bisphosphonate therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01233557

United Kingdom
Aberdeen Royal Infirmary
Aberdeen, United Kingdom, AB25 2ZN
Sponsors and Collaborators
University of Aberdeen
Principal Investigator: Donald Bissett, M.D. NHS Grampian

Responsible Party: University of Aberdeen Identifier: NCT01233557     History of Changes
Other Study ID Numbers: 10/S0802/36
First Posted: November 3, 2010    Key Record Dates
Last Update Posted: November 5, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Prostatic Neoplasms
Bone Resorption
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Bone Diseases
Musculoskeletal Diseases